Bystander effect tumoricidal therapy

Details Bystander effect tumoricidal therapy Bystander effect tumoricidal therapy

A - Human Necessities

61

K

A61K 48/00 (2006.01) A61K 31/505 (2006.01) A61K 31/52 (2006.01) A61K 31/70 (2006.01) A61K 38/45 (2006.01) A61K 39/00 (2006.01)

Patent

CA 2134763

2134763 9321959 PCTABS00027 A method for treating a tumor involves the initial identification of the tumor as one displaying a "bystander effect", whereby in vivo transfer of a gene conferring sensitivity to chemotherapeutic agent affects both transformed and non-transformed tumor cells. Into a tumor thus characterized is introduced in situ a retroviral vector containing the sensitizing gene. The retroviral vector, which may be a replication-defective or a replication-competent, can be introduced directly (if it is replication-competent) or can be provided by means of a packaging cell line. Treatment of the patient with the chemotherapeutic agent thereafter effects tumor regression when as few as 10 % of tumor cells are transformed, while normal tissue is not damaged. The anti-tumor impact of the treatment can be increased when the transducing vector also encodes an immune response-enhance substance such as IL-2 or another cytokine.

Affiliated with

Also associated with

Rating

Bystander effect tumoricidal therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bystander effect tumoricidal therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bystander effect tumoricidal therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1769227